Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPR NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.14$2.53$0.69▼$4.18$808.25M0.9120.25 million shs7.43 million shsLGNDLigand Pharmaceuticals$221.41+5.3%$212.17$98.89▼$247.38$4.21B1.2237,064 shs249,976 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics0.00%+57.00%+34.76%-7.65%+260.92%LGNDLigand Pharmaceuticals0.00%-8.33%+1.08%+10.44%+99.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.14$2.53$0.69▼$4.18$808.25M0.9120.25 million shs7.43 million shsLGNDLigand Pharmaceuticals$221.41+5.3%$212.17$98.89▼$247.38$4.21B1.2237,064 shs249,976 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics0.00%+57.00%+34.76%-7.65%+260.92%LGNDLigand Pharmaceuticals0.00%-8.33%+1.08%+10.44%+99.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.00Hold$5.5476.43% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.7116.40% UpsideCurrent Analyst Ratings BreakdownLatest ESPR and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.164/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.004/28/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $252.004/21/2026ESPREsperion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$403.14M2.00N/AN/A($1.26) per share-2.49LGNDLigand Pharmaceuticals$268.09M16.55$8.26 per share26.79$49.77 per share4.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$22.68M-$0.17N/A14.272.55-3.66%N/A-3.93%N/ALGNDLigand Pharmaceuticals$124.45M$5.8330.0429.561.7155.95%16.19%11.13%5/14/2026 (Estimated)Latest ESPR and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/7/2026Q1 2026ESPREsperion Therapeutics-$0.04-$0.10-$0.06-$0.10$84.52 million$80.10 million3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.541.19LGNDLigand Pharmaceuticals0.4521.2821.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200257.40 million253.03 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableESPR and LGND HeadlinesRecent News About These CompaniesF m Investments LLC Has $8.72 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND55 minutes ago | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $262.00 Price Target at Royal Bank Of CanadaMay 8 at 1:32 PM | marketbeat.comLigand Pharmaceuticals Q1 Earnings Call HighlightsMay 8 at 2:05 AM | marketbeat.comLigand: Q1 Earnings SnapshotMay 7 at 10:33 AM | chron.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down After Earnings MissMay 7 at 10:19 AM | marketbeat.comWhat is HC Wainwright's Estimate for LGND Q3 Earnings?May 7 at 8:16 AM | marketbeat.comLigand Reports First Quarter 2026 Financial ResultsMay 7 at 7:00 AM | globenewswire.comLigand Pharmaceuticals (LGND) Projected to Post Earnings on ThursdayMay 7 at 3:25 AM | marketbeat.comOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced ...May 6 at 1:20 PM | caledonianrecord.comCLigand to Participate in May Investor ConferencesMay 5, 2026 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 SharesMay 5, 2026 | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of StockMay 4, 2026 | marketbeat.comBank of America Securities Keeps Their Buy Rating on Ligand Pharma (LGND)May 2, 2026 | theglobeandmail.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KSMay 2, 2026 | marketbeat.comHC Wainwright Brokers Increase Earnings Estimates for LGNDMay 1, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $289.00 Price Target at HC WainwrightMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceApril 30, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - Here's WhyApril 29, 2026 | marketbeat.comMoody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGNDApril 29, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR and LGND Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$3.14 0.00 (0.00%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.14 +0.00 (+0.16%) As of 05/8/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Ligand Pharmaceuticals NASDAQ:LGND$221.41 +11.08 (+5.27%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$221.16 -0.25 (-0.11%) As of 05/8/2026 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
